Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

36.50 USD -0.23 (-0.63%)
Official Closing Price Updated: 5:37 PM EST, Jan 20, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Pfizer

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Psychedelics Could Become the Next Health and Wellness Trend
FN Media Group Presents Microsmallcap.com Market Commentary 
From PR Newswire
Psychedelics Could Become the Next Health and Wellness Trend
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Should you invest in Nio Inc, Nikola Corp, Pfizer, Snap, or Flex?
InvestorsObserver issues critical PriceWatch Alerts for NIO, NKLA, PFE, SNAP, and FLEX. 
From PR Newswire
2nd Annual Gabelli Funds – Columbia Business School Healthcare Symposium (Virtual)
Join us as we discuss today’s pressing healthcare issues. 
From Business Wire News Releases
Transgene: Acceptance of Late Breaking Abstract at Upcoming SITC 2020 Conference, on The Detailed Results From Clinical Study of TG4001 in Combination With Avelumab in Advanced HPV-positive Cancers
Regulatory News: 
From Business Wire News Releases
Should you invest in Pfizer, Autodesk, Caterpillar, Vipshop Holdings, or JinkoSolar?
InvestorsObserver issues critical PriceWatch Alerts for PFE, ADSK, CAT, VIPS, and JKS. 
From PR Newswire
ViiV Healthcare receives positive CHMP opinion for long-acting regimen for the treatment of HIV
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced that the Committee for Medicinal Products for Human Use... 
From Business Wire News Releases
Orphan Drugs Market 2020 | Global Industry Overview, Sales Revenue, Demand and Opportunity 2025
Tags Health & Medicine
From AB Newswire
iBio Announces Appointment of Dr. Linda Armstrong to Board of Directors
From GlobeNewswire News Releases
Targeted Therapies for Glioblastoma Becoming Critical As Increasing Incidence of Brain Cancer Rises
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Targeted Therapies for Glioblastoma Becoming Critical As Increasing Incidence of Brain Cancer Rises
Financialnewsmedia.com News Commentary 
From PR Newswire
CStone Announces Completion of $200 million Share Sale to Pfizer
- Share sale brings into effect strategic collaboration agreement 
From PR Newswire
PENELOPE-B Trial of IBRANCE® (palbociclib) in Early Breast Cancer Did Not Meet Primary Endpoint
The German Breast Group (GBG) and Pfizer Inc. (NYSE: PFE) today announced that the collaborative Phase 3 PENELOPE-B trial did not meet the primary endpoint of improved invasive disease-free survival... 
From Business Wire News Releases
New Report Projects Immunotherapy Drug Market to Reach $274.6 Billion by 2025 with CAGR of 11.0%
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
New Report Projects Immunotherapy Drug Market to Reach $274.6 Billion by 2025 with CAGR of 11.0%
- FN Media Group Presents USA News Group News Commentary 
From PR Newswire
Pfizer Announces Positive Phase 3 Top-line Results for Once-Weekly Investigational Long-Acting Human Growth Hormone to Treat Children with Growth Hormone Deficiency
Pfizer Inc. (NYSE: PFE) and OPKO Health Inc. (NASDAQ: OPK) announced today that C0311002, a Phase 3, randomized, multicenter, open-label, crossover study evaluating somatrogon dosed once-weekly in... 
From Business Wire News Releases
Pfizer and Sangamo Dose First Participant in Phase 3 Study Evaluating Hemophilia A Gene Therapy Treatment
Pfizer Inc. (NYSE: PFE) and Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today announced that the first participant has been dosed in the Phase 3 AFFINE study of... 
From Business Wire News Releases
Exact Sciences and Pfizer Extend and Amend Cologuard® Promotion Agreement
Successful collaboration will continue to support Cologuard adoption through 2022 
From PR Newswire
Catalio Capital Management LP Closes Oversubscribed Venture Fund II at $100 Million Hard Cap
Catalio Capital Management LP (Catalio), a prominent life sciences investment firm, announced today the close of its second venture fund, Catalio Nexus II. The fund was oversubscribed and closed at its... 
From Business Wire News Releases
BioNTech and Pfizer Initiate Rolling Submission to European Medicines Agency for SARS-CoV-2 Vaccine Candidate BNT162b2
From GlobeNewswire News Releases
SpringWorks Therapeutics Announces Clinical Collaboration with Pfizer Inc. to Evaluate Nirogacestat in Combination with PF‐06863135 in Patients with Relapsed or Refractory Multiple Myeloma
Fifth industry collaboration to evaluate nirogacestat as a BCMA potentiator across modalities 
From GlobeNewswire News Releases
ViiV Healthcare presents a new podcast about the Power of Being Seen
Ten-episode series available October 6th features conversations with leading cultural figures and influencers discussing how Black gay and queer men want to be seen 
From PR Newswire
Pfizer Receives FDA Fast Track Designation for Duchenne Muscular Dystrophy Investigational Gene Therapy
Pfizer Inc. (NYSE: PFE) today announced that its investigational gene therapy candidate (PF-06939926) being developed to treat Duchenne muscular dystrophy (DMD) received Fast Track designation from the... 
From Business Wire News Releases
CStone, Pfizer Enter into Strategic Collaboration to Address Oncological Needs in China
CStone Pharmaceuticals (“CStone”, HKEX: 2616)] and Pfizer Investment Co. Ltd. ("Pfizer Investment") and Pfizer Corporation Hong Kong Limited ("Pfizer Hong Kong") (both of which are subsidiaries of... 
From Business Wire News Releases
U.S. FDA Approves Pfizer’s XELJANZ® (tofacitinib) for the Treatment of Active Polyarticular Course Juvenile Idiopathic Arthritis
Pfizer Inc. (NYSE: PFE) announced today that the United States (U.S.) Food and Drug Administration (FDA) approved XELJANZ® (tofacitinib) for the treatment of children and adolescents 2 years and older... 
From Business Wire News Releases
Improving Diagnostic Devices Expand Patient Monitoring Capabilities
FinancialBuzz.com News Commentary 
From PR Newswire
Pfizer Declares Fourth-Quarter 2020 Dividend
The board of directors of Pfizer Inc. (NYSE:PFE) declared a 38-cent fourth-quarter 2020 dividend on the company’s common stock, payable December 1, 2020, to holders of the Common Stock of record at the... 
From Business Wire News Releases
IDEAYA and Pfizer Expand Clinical Trial Collaboration and Supply Agreement to Evaluate Clinical Combination of IDE196 and Crizotinib in Solid Tumors Harboring GNAQ or GNA11 Mutations
IDEAYA Biosciences, Inc. (NASDAQ: IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics to treat cancer, today announced that it has... 
From PR Newswire
Javelin Biotech Aims to Develop Industry-Leading “Organ-on-a-Chip” Predictive Pharmacokinetics Platform in Collaboration with Pfizer Inc.
Javelin Biotech today announces a 3-year collaboration with Pfizer to design and build a platform to evaluate ADME properties of small molecule drugs. 
From Business Wire News Releases
ViiV Healthcare Announces Availability of CABENUVA and VOCABRIA in Canada
From PR Newswire
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.